CHMP positive opinion for CASGEVY conditional EU approval in sickle cell and beta thalassemia

CRISPR Therapeutics AG

EMA's CHMP adopted positive opinion for conditional approval of CASGEVY (exagamglogene autotemcel) for severe sickle cell disease and transfusion-dependent beta thalassemia.
CASGEVY is a CRISPR/Cas9 gene-edited therapy jointly developed by CRISPR Therapeutics and Vertex Pharmaceuticals.
European Commission decision expected in February 2024; conditional marketing authorizations are valid one year, renewable annually.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.